Varenicline for the Treatment of Smokeless Tobacco

NCT ID: NCT00813917

Last Updated: 2012-07-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 76 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-02-28
• Study Completion Date: 2011-01-31

Brief Summary

Varenicline (Chantix™, Pfizer) is a novel selective nicotinic receptor partial agonist with specificity for the α4β2 nicotine acetylcholine receptor that has demonstrated remarkable efficacy for increasing long-term tobacco abstinence rates in cigarette smokers. The novel mechanism of action of varenicline potentially circumvents the limitations of using nicotine replacement therapy or bupropion pharmacotherapy in ST users. The overall goal of this line of research is to develop effective pharmacologic treatments for ST users to increase long-term (≥ 6 months) abstinence rates. The central hypothesis of this application is that varenicline is efficacious for the treatment of ST users.

Detailed Description

In the United States, approximately 7.7 million individuals older than 12 years of age report current (past month) use of smokeless tobacco (ST). ST use has been associated with oral and extra-oral cancer as well as cardiovascular and cerebrovascular disease. To date, no pharmacotherapies have been shown to increase long-term (≥ 6 months) abstinence rates in ST users. Novel pharmacotherapies that decrease withdrawal symptoms and nicotine self-administration need to be tested in ST users. Varenicline (Chantix™, Pfizer) is a novel selective nicotinic receptor partial agonist with specificity for the α4β2 nicotine acetylcholine receptor that has demonstrated remarkable efficacy for increasing long-term tobacco abstinence rates in cigarette smokers. The novel mechanism of action of varenicline potentially circumvents the limitations of using nicotine replacement therapy or bupropion pharmacotherapy in ST users. The overall goal of this line of research is to develop effective pharmacologic treatments for ST users to increase long-term (≥ 6 months) abstinence rates. The central hypothesis of this application is that varenicline is efficacious for the treatment of ST users. To evaluate this hypothesis, we will conduct a pilot study to obtain preliminary estimates of efficacy of 12-weeks of varenicline for increasing the prolonged and point prevalence tobacco abstinence rates at 12 weeks (end-of-treatment) in ST users. We will also evaluate the effect of varenicline on nicotine withdrawal symptoms and tobacco craving. If the results are promising, we will plan for a multicenter, randomized, double-blinded, placebo-controlled clinical trial with the Oregon Research Institute in Eugene, OR, to investigate the efficacy of varenicline to increase long-term (≥ 6 months) abstinence rates in ST users.

Conditions

Nicotine Dependence

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

varenicline

Group Type: ACTIVE_COMPARATOR

varenicline

Intervention Type: DRUG

12 weeks of varenicline 1 mg by mouth twice per day

Placebo

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

12 weeks of placebo (double blinded) by mouth twice per day

Interventions

varenicline

12 weeks of varenicline 1 mg by mouth twice per day

Intervention Type: DRUG

placebo

12 weeks of placebo (double blinded) by mouth twice per day

Intervention Type: DRUG

Other Intervention Names

Chantix; Chantix placebo

Eligibility Criteria

Inclusion Criteria

Subjects will be eligible to participate if they:

1. Are at least 18 years of age

2. Have used ST daily for the past 12 months (regular user)

3. Identify ST as their primary tobacco product

4. Are in general good health (determined by medical history and screening physical examination)

5. Has provided written informed consent to participate

6. Are able to participate in all aspects of the study

Exclusion Criteria

Individuals will be excluded from study participation if they:

1. Are currently (in previous 30 days) using other behavioral or pharmacologic tobacco cessation programs (i.e., behavioral therapy, nicotine replacement therapy, clonidine, bupropion SR, or doxepin)

2. Have self-reported current, untreated depression or a Beck Depression Inventory (BDI-II) Score of ≥ 20

3. Have, as defined by the C-SSRS (Columbia-Suicide Severity Rating Scale);current non-specific suicidal thoughts, or have a lifetime history of a suicidal attempt (defined as "potentially self-injurious act committed with at least some wish to die, as a result of act.")

4. History of psychosis or bipolar disorder

5. Are currently pregnant or lactating or is of childbearing potential and not willing to use any form of contraception

6. Have another member of their household already participating in this study

7. Are allergic to varenicline

8. Describe having a medical history of:

• Unstable angina
• Myocardial infarction within the past 3 months
• Cardiac dysrhythmia other than medication-controlled atrial fibrillation or PSVT
• Medically-treated or untreated hypertension with BP ≥ 200 systolic OR ≥ 100 diastolic
• Have other medical or psychiatric conditions that would exclude the participant

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institutes of Health (NIH)

NIH

Sponsor Role: collaborator

Mayo Clinic

OTHER

Sponsor Role: lead

Responsible Party

Jon Ebbert

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jon O. Ebbert, M.D.

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Nicotine Research Program

Rochester, Minnesota, United States

Countries

United States

References

Ebbert JO, Croghan IT, Severson HH, Schroeder DR, Hays JT. A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in Midwestern United States. Nicotine Tob Res. 2011 Sep;13(9):820-6. doi: 10.1093/ntr/ntr078. Epub 2011 Apr 18.

Reference Type: RESULT

PMID: 21504885 (View on PubMed)

Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 May 5;5(5):CD006103. doi: 10.1002/14651858.CD006103.pub8.

Reference Type: DERIVED

PMID: 37142273 (View on PubMed)

Other Identifiers

CA132621-01A1

Identifier Type: -

Identifier Source: secondary_id

08-005359

Identifier Type: -

Identifier Source: org_study_id